<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01836029</url>
  </required_header>
  <id_info>
    <org_study_id>VRXP-A202</org_study_id>
    <nct_id>NCT01836029</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VentiRx Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VentiRx Pharmaceuticals Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the progression-free survival of patients with
      recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with
      VTX-2337 + cisplatin or carboplatin + 5-FU + cetuximab versus patients treated with
      cisplatin or carboplatin + 5-FU + cetuximab alone (standard-of-care; SOC).  Safety and
      overall survival will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel group study to evaluate the
      safety and efficacy of VTX 2337 in combination with cisplatin or carboplatin, 5-FU and
      cetuximab in prolonging the progression-free survival in subjects with recurrent or
      metastatic squamous cell carcinoma of the head and neck.

      OBJECTIVES:

      Primary Objective:

      To compare the efficacy of VTX 2337 plus SOC to SOC alone in prolonging the PFS of patients
      with recurrent or metastatic SCCHN.

      Secondary Objectives:

      To compare  the following between the two treatment groups:

        -  Safety of VTX 2337 by adverse events, including clinically significant changes in
           physical examination, peripheral blood hematology, serum chemistry, urinalysis, and
           ECG.

        -  Efficacy of VTX 2337 plus SOC in prolonging the OS of patients with recurrent or
           metastatic SCCHN.

        -  Efficacy of VTX-2337 plus SOC on ORR, DOBR, DCR, and DDC by irRECIST and evaluation by
           independent radiology review.

      Exploratory Objectives:

        -  To compare genetic polymorphisms that may impact the response of patients to a TLR8
           agonist or to cetuximab between the two treatment groups.

        -  To compare immune biomarker response to VTX 2337 plus SOC as measured by a multiplexed
           panel of cytokines, chemokines, and inflammatory markers between the two treatment
           groups.

        -  To compare the effect of immune cell subsets within the tumor on response to VTX-2337
           and/or clinical outcome, as measured by immunohistochemistry in primary tumor tissue
           between the two treatment groups.

        -  To assess the PK of VTX-2337.

      OUTLINE:

      Subjects will be screened for eligibility (within 14 days) and qualified subjects will be
      randomized 1:1 to 1 of 2 treatment groups: SOC + VTX 2337 or SOC + placebo.

      Tumor assessments will be by CT or MRI starting at Week 12 (± 3 days), then at Week 18 (± 3
      days) and every 8 weeks (± 7 days) thereafter. Response will be evaluated by immune-related
      RECIST criteria (irRECIST) and confirmed by an independent radiologist.

      Upon independent confirmation of disease progression, active participation in the study is
      complete and subjects will undergo the End of Treatment evaluations.

      Subjects will be followed for survival until ~12 months after the last subject is
      randomized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To compare the efficacy of VTX-2337 plus SOC to SOC alone in prolonging the PFS of patients with recurrent or metastatic SCCHN.</measure>
    <time_frame>approximately 9 months after the last patient is randomized</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare  the safety of VTX-2337 plus SOC versus SOC alone by adverse events, including clinically significant changes in physical examination, peripheral blood hematology, serum chemistry, urinalysis, and ECG.</measure>
    <time_frame>Approximately 9 months after the last patient is randomized</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of VTX-2337 plus SOC versus SOC alone in prolonging the OS of patients with recurrent or metastatic SCCHN.</measure>
    <time_frame>Approximately 12 months after the last patient is randomized</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of VTX-2337 plus SOC to SOC alone on objective response rate.</measure>
    <time_frame>Approximately 9 months after the last patient is randomized</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of VTX-2337 plus SOC to SOC alone on duration of best response.</measure>
    <time_frame>Approximately 9 months after the last patient is randomized.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of VTX-2337 plus SOC to SOC alone on disease control rate.</measure>
    <time_frame>Approximately 9 months after the last patient is randomized.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of VTX-2337 plus SOC to SOC alone on duration of disease control.</measure>
    <time_frame>Approximately 9 months after the last patient is randomized.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>To compare the effect of immune cell subsets within the tumor on response to treatment and/or clinical outcome.</measure>
    <time_frame>Approximately 9 months after the last patient is randomized</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>To compare the genetic polymorphisms that may impact the response of patients to a TLR8 agonist or to cetuximab between the two treatment groups.</measure>
    <time_frame>Screening</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>To compare the immune biomarker response as measured by a multiplexed panel of cytokines, chemokines, and inflammatory markers between the two treatment groups.</measure>
    <time_frame>Screening, Cycle 1 Day 8, and Cycle 3 Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>To assess PK of VTX-2337</measure>
    <time_frame>Cycle 1 Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <arm_group>
    <arm_group_label>chemotherapy and cetuximab plus VTX-2337</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.
Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.
5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.
Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy and cetuximab plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.
Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.
5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.
Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VTX-2337</intervention_name>
    <description>TLR8 Agonist</description>
    <arm_group_label>chemotherapy and cetuximab plus VTX-2337</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>chemotherapy and cetuximab plus VTX-2337</arm_group_label>
    <arm_group_label>chemotherapy and cetuximab plus placebo</arm_group_label>
    <other_name>paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>chemotherapy and cetuximab plus VTX-2337</arm_group_label>
    <arm_group_label>chemotherapy and cetuximab plus placebo</arm_group_label>
    <other_name>Platin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <arm_group_label>chemotherapy and cetuximab plus VTX-2337</arm_group_label>
    <arm_group_label>chemotherapy and cetuximab plus placebo</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Efudex</other_name>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>chemotherapy and cetuximab plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability and willingness to provide written informed consent

          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and
             neck

          -  Locoregionally recurrent or metastatic disease that has not previously been treated
             with systemic therapy of recurrent or metastatic disease

          -  At least one measurable lesion on screening CT or MRI

          -  18 years of age or older

          -  ECOG performance status of 0 or 1

          -  Acceptable bone marrow, renal, and hepatic function based upon screening lab tests

          -  Willingness to use medically acceptable contraception

          -  For females with reproductive potential: a negative serum pregnancy test

        Exclusion Criteria:

          -  Disease which is amenable to curative local therapy

          -  Nasopharyngeal, salivary gland, lip or sinonasal carcinoma

          -  Surgery or irradiation ≤ 4 weeks prior to randomization

          -  Prior systemic anti-cancer therapy, unless administered for localized SCCHN and
             completed at least 6 months prior to disease recurrence

          -  Treatment with an investigational agent ≤ 30 days prior to randomization

          -  Treatment with corticosteroids within 2 weeks

          -  A requirement for chronic systemic immunosuppressive therapy for any reason

          -  Prior serious infusion reaction to cetuximab

          -  Treatment with an immunotherapy within 30 days

          -  Known brain metastases, unless stable for at least 28 days

          -  Active autoimmune disease currently requiring therapy

          -  Known infection with HIV

          -  Significant cardiac disease within 6 months

          -  Pregnant or breast-feeding females

          -  History of another primary malignancy, with the exception of (i) curatively resected
             non-melanoma skin cancer, (ii) curatively treated in situ cervical cancer, or (iii)
             other malignancy curatively treated with no evidence of disease and no anticancer
             therapy administered for 3 years prior to randomization, with the exception of
             adjuvant hormonal therapy for breast cancer

          -  Other conditions or circumstances that could interfere with the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Ferris, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristi Manjarrez</last_name>
    <phone>206-689-2259</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laiza Espinoza</last_name>
      <phone>480-301-4077</phone>
      <email>espinozabriones.laiza@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kelly Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tower Hematology Oncology Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Ford</last_name>
      <phone>310-285-7268</phone>
      <email>linda.ford@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Solomon Hamburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence (CCARE)</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Bilawa</last_name>
      <phone>760-737-2666</phone>
      <email>mbilawa@pacificoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Kosmo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanna Lee</last_name>
      <phone>858-822-4171</phone>
      <email>sml012@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Daniels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Tse</last_name>
      <phone>323-865-0514</phone>
      <email>tse_g@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Gitlitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Colvin</last_name>
      <phone>720-848-0664</phone>
      <email>tiffany.colvin@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Jimeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Healthcare System</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Ciminelli</last_name>
      <phone>303-399-8020</phone>
      <phone_ext>3865</phone_ext>
      <email>barbara.ciminelli@va.gov</email>
    </contact>
    <investigator>
      <last_name>Daniel Bowles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Combs</last_name>
      <phone>302-623-4639</phone>
      <email>kcombs@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guarino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Lossing</last_name>
      <phone>321-841-4704</phone>
      <email>marina.lossing@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer Tseng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Cancer Care, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <phone>706-353-2990</phone>
      <phone_ext>279</phone_ext>
      <email>jhodgson@negacancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renea Stinson</last_name>
      <phone>404-778-4576</phone>
      <email>renea.stinson@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Nabil Saba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxana Vintilescu</last_name>
      <phone>312-695-1335</phone>
      <email>claudia.vintilescu@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Agulnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Ward</last_name>
      <phone>217-383-4011</phone>
      <email>joshua.ward@carle.com</email>
    </contact>
    <investigator>
      <last_name>Ronnie Luyun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Hapgood</last_name>
      <phone>913-588-2566</phone>
      <email>mhapgood@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Prakash Neupane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crescent City Research Consortium, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ann Ostroske</last_name>
      <phone>504-855-8220</phone>
      <email>maryann.ostroske@wjmc.org</email>
    </contact>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert W. Veith, MD, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006-2936</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha Wendling</last_name>
      <phone>504-455-0600</phone>
      <email>alishaw23@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Robert Vieth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Chase</last_name>
      <phone>207-396-7634</phone>
      <email>chasee@mccm.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Dugan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara McMonagle</last_name>
      <email>kmcmonagle@genevausa.org</email>
    </contact>
    <investigator>
      <last_name>LTC Corey Carter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farzana Masood</last_name>
      <phone>617-632-6725</phone>
      <email>farzana_masood@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pearce</last_name>
      <phone>313-916-1784</phone>
      <email>tpearce1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Doyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priya Spencer-Singh</last_name>
      <phone>313-576-9679</phone>
      <email>singhp@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ammar Sukari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Cancer Care, LLP</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Martin</last_name>
      <phone>314-291-3312</phone>
      <email>kelli.a.martin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jaun D Cuevas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey Johnson</last_name>
      <phone>314-362-0208</phone>
      <email>ljohnson@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Adkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Yule</last_name>
      <phone>702-384-0013</phone>
      <email>s.yule@sncrf.org</email>
    </contact>
    <investigator>
      <last_name>John Ellerton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Williams</last_name>
      <phone>603-650-6056</phone>
      <email>ian.r.williams@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Specialists, P.A.</name>
      <address>
        <city>Denville</city>
        <state>New Jersey</state>
        <zip>07834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Schmitz</last_name>
      <phone>973-625-6377</phone>
      <email>serenaschmitz@saintclares.org</email>
    </contact>
    <investigator>
      <last_name>Rashid Abbasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seana Krauss</last_name>
      <phone>551-996-8612</phone>
      <email>skrauss@hackensackumc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Alter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmeen Beckett</last_name>
      <phone>973-972-3173</phone>
      <email>barberys@njms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Lilian Pliner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Babu, RN</last_name>
      <phone>212-824-7295</phone>
      <email>rita.babu@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adnan Khan</last_name>
      <phone>(212) 824-7337</phone>
      <email>adnan.khan@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Krzysztof Misiukiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Hentschel</last_name>
      <phone>631-638-0839</phone>
      <email>patricia.hentschel@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Roger Keresztes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dale Flowers</last_name>
      <phone>919-843-3875</phone>
      <email>dale_flowers@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>David Hayes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Nortman</last_name>
      <phone>513-584-5725</phone>
      <email>natalie.nortman@uc.edu</email>
    </contact>
    <investigator>
      <last_name>John Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Rahe</last_name>
      <phone>216-636-1242</phone>
      <email>rahem@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Tobenna Nwizu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Halloway</last_name>
      <phone>216-844-8111</phone>
      <email>kathleen.halloway@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Michael Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Charles Medical Center</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Boone</last_name>
      <phone>541-706-3790</phone>
      <email>mboone@cascadehealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Coralia Calomeni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Lukes Cancer Centre</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Cabral</last_name>
      <phone>484-503-4151</phone>
      <email>rosemarie.cabral@sluhn.org</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Agarwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State Hershey Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Crain</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>289630</phone_ext>
      <email>mcrain@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Salah Almokadem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Schwabenbauer</last_name>
      <phone>412-623-6793</phone>
      <email>panianba@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Bauman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Woodruff</last_name>
      <phone>843-782-6349</phone>
      <email>woodrufk@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Keisuke Shirai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Inman</last_name>
      <phone>901-683-0055</phone>
      <phone_ext>1236</phone_ext>
      <email>cinman@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Moon J Fenton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Villalobos</last_name>
      <phone>214-648-7010</phone>
      <email>isabel.villalobos@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Randall Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Smith</last_name>
      <phone>210-292-3546</phone>
      <email>peggy.s.smith56.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Alexander Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PD</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Crandon</last_name>
      <phone>703-208-3148</phone>
      <email>sonja.crandon@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenandoah Oncology Associates, PC</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips</last_name>
      <phone>540-662-1108</phone>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>William Houck III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Chaudhry</last_name>
      <phone>509-462-2273</phone>
      <email>chaudhrym@nwrm.com</email>
    </contact>
    <investigator>
      <last_name>Arvind Chaudhry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Marshall</last_name>
      <phone>360-775-5144</phone>
      <email>kathryn.e.marshall2.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>LTC Wayne J. Harsha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Koziel</last_name>
      <phone>414-805-0956</phone>
      <email>akoziel@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>April 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCCHN</keyword>
  <keyword>HNSCC</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
